Literature DB >> 34117809

Biochemistry, structure, and cellular internalization of a four nanobody-bearing Fc dimer.

Eric Chabrol1,2, Charline Fagnen3,4, Sophie Landron1, Estelle Marcheteau1, Johann Stojko1, Sophie-Pénélope Guenin1, Mathias Antoine1,5, Benjamin Fould1, Gilles Ferry1, Jean A Boutin6,7, Catherine Vénien-Bryan3.   

Abstract

VHH stands for the variable regions of heavy chain only of camelid IgGs. The VHH family forms a set of interesting proteins derived from antibodies that maintain their capacity to recognize the antigen, despite their relatively small molecular weight (in the 12,000 Da range). Continuing our exploration of the possibilities of those molecules, we chose to design alternative molecules with maintained antigen recognition, but enhanced capacity, by fusing four VHH with one Fc, the fragment crystallizable region of antibodies. In doing so, we aimed at having a molecule with superior quantitative antigen recognition (×4) while maintaining its size below the 110 kDa. In the present paper, we described the building of those molecules that we coined VHH2 -Fc-VHH2 . The structure of VHH2 -Fc-VHH2 in complex with HER2 antigen was determined using electronic microscopy and modeling. The molecule is shown to bind four HER2 proteins at the end of its flexible arms. VHH2 -Fc-VHH2 also shows an internalization capacity via HER2 receptor superior to the reference anti-HER2 monoclonal antibody, Herceptin®, and to a simple fusion of two VHH with one Fc (VHH2 -Fc). This new type of molecules, VHH2 -Fc-VHH2 , could be an interesting addition to the therapeutic arsenal with multiple applications, from diagnostic to therapy.
© 2021 The Protein Society.

Entities:  

Keywords:  VHH; antibody like molecules; cellular uptake; characterization; subcellular localization

Mesh:

Substances:

Year:  2021        PMID: 34117809      PMCID: PMC8376420          DOI: 10.1002/pro.4147

Source DB:  PubMed          Journal:  Protein Sci        ISSN: 0961-8368            Impact factor:   6.993


  37 in total

1.  Heavy chain-only antibodies and tetravalent bispecific antibody neutralizing Staphylococcus aureus leukotoxins.

Authors:  Benoît-Joseph Laventie; Hendrik Jan Rademaker; Maher Saleh; Ernie de Boer; Rick Janssens; Tristan Bourcier; Audrey Subilia; Luc Marcellin; Rien van Haperen; Joyce H G Lebbink; Tao Chen; Gilles Prévost; Frank Grosveld; Dubravka Drabek
Journal:  Proc Natl Acad Sci U S A       Date:  2011-09-19       Impact factor: 11.205

2.  EMAN2: an extensible image processing suite for electron microscopy.

Authors:  Guang Tang; Liwei Peng; Philip R Baldwin; Deepinder S Mann; Wen Jiang; Ian Rees; Steven J Ludtke
Journal:  J Struct Biol       Date:  2006-06-08       Impact factor: 2.867

3.  VHH characterization. Comparison of recombinant with chemically synthesized anti-HER2 VHH.

Authors:  Lucie Hartmann; Thomas Botzanowski; Mathieu Galibert; Magali Jullian; Eric Chabrol; Gabrielle Zeder-Lutz; Valérie Kugler; Johann Stojko; Jean-Marc Strub; Gilles Ferry; Lukasz Frankiewicz; Karine Puget; Renaud Wagner; Sarah Cianférani; Jean A Boutin
Journal:  Protein Sci       Date:  2019-08-29       Impact factor: 6.725

Review 4.  Cryo-electron microscopy and X-ray crystallography: complementary approaches to structural biology and drug discovery.

Authors:  Catherine Vénien-Bryan; Zhuolun Li; Laurent Vuillard; Jean Albert Boutin
Journal:  Acta Crystallogr F Struct Biol Commun       Date:  2017-03-29       Impact factor: 1.056

Review 5.  Antibody-siRNA conjugates: drugging the undruggable for anti-leukemic therapy.

Authors:  Jogender Tushir-Singh
Journal:  Expert Opin Biol Ther       Date:  2016-12-23       Impact factor: 4.388

6.  VHH characterization.Recombinant VHHs: Production, characterization and affinity.

Authors:  Eric Chabrol; Johann Stojko; Alexandre Nicolas; Thomas Botzanowski; Benjamin Fould; Mathias Antoine; Sarah Cianférani; Gilles Ferry; Jean A Boutin
Journal:  Anal Biochem       Date:  2019-10-30       Impact factor: 3.365

Review 7.  Antibody Therapy for the Control of Viral Diseases: An Update.

Authors:  Miriam Dibo; Eduardo C Battocchio; Lucas M Dos Santos Souza; Matheus D Veloso da Silva; Bruna K Banin-Hirata; Milena M M Sapla; Poliana Marinello; Sérgio P D Rocha; Lígia C Faccin-Galhardi
Journal:  Curr Pharm Biotechnol       Date:  2019       Impact factor: 2.837

8.  Design, synthesis, and computational validation of novel compounds selectively targeting HER2-expressing breast cancer.

Authors:  Samia A Elseginy; Rania Hamdy; Varsha Menon; Ahmed M Almehdi; Raafat El-Awady; Sameh S M Soliman
Journal:  Bioorg Med Chem Lett       Date:  2020-10-29       Impact factor: 2.823

9.  Fusion of hIgG1-Fc to 111In-anti-amyloid single domain antibody fragment VHH-pa2H prolongs blood residential time in APP/PS1 mice but does not increase brain uptake.

Authors:  Maarten Rotman; Mick M Welling; Marlinde L van den Boogaard; Laure Grand Moursel; Linda M van der Graaf; Mark A van Buchem; Silvère M van der Maarel; Louise van der Weerd
Journal:  Nucl Med Biol       Date:  2015-03-18       Impact factor: 2.408

Review 10.  CAR T Cell Therapy for Neuroblastoma.

Authors:  Rebecca M Richards; Elena Sotillo; Robbie G Majzner
Journal:  Front Immunol       Date:  2018-10-16       Impact factor: 7.561

View more
  1 in total

1.  Biochemistry, structure, and cellular internalization of a four nanobody-bearing Fc dimer.

Authors:  Eric Chabrol; Charline Fagnen; Sophie Landron; Estelle Marcheteau; Johann Stojko; Sophie-Pénélope Guenin; Mathias Antoine; Benjamin Fould; Gilles Ferry; Jean A Boutin; Catherine Vénien-Bryan
Journal:  Protein Sci       Date:  2021-06-17       Impact factor: 6.993

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.